{"id":27317,"date":"2024-02-22T14:49:16","date_gmt":"2024-02-22T19:49:16","guid":{"rendered":"https:\/\/myeloma.ca\/?p=27317"},"modified":"2024-02-22T14:49:18","modified_gmt":"2024-02-22T19:49:18","slug":"telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/","title":{"rendered":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF)<\/strong> (la \u00ab\u202f<strong>Soci\u00e9t\u00e9<\/strong>\u202f\u00bb ou \u00ab\u202f<strong>Telo<\/strong>\u202f\u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab\u202fMM\u202f\u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital g\u00e9n\u00e9ral juif de Montr\u00e9al, au Qu\u00e9bec (Canada). L\u2019essai est r\u00e9pertori\u00e9 sur le site Web de la <em>National Library of Medicine <\/em>(clinicaltrials.gov)\u202fsous la rubrique NCT05530096\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05530096\" target=\"_blank\" rel=\"noreferrer noopener\">Lire la suite&#8230;<\/a> &nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab\u202fSoci\u00e9t\u00e9\u202f\u00bb ou \u00ab\u202fTelo\u202f\u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab\u202fMM\u202f\u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88,53],"tags":[],"class_list":["post-27317","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=27317"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27317\/revisions"}],"predecessor-version":[{"id":27318,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27317\/revisions\/27318"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=27317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=27317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=27317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}